Ketogenic Diet in MASLD-related cACLD
NCT06537466 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2024-08-05
Summary
The investigators hypothesize that very low ketogenic diet could represent a new therapeutic option in the management of patients with MASLD and cACLD. Therefore, the investigator propose a randomized controlled study that evaluates the impact of two dietary protocols -Mediterranean diet, and very low ketogenic diet- the MD and the VLCKD, in individuals with cACLD secondary to MASLD.
Conditions
- Steatohepatitis, Nonalcoholic
- Steatosis of Liver
- Cirrhosis, Liver
Interventions
- DIETARY_SUPPLEMENT
-
Mediterranean diet
This equilibrated diet has a caloric value 10% below the total metabolic expenditure of each individual. The total metabolic expenditure is calculated from the basal metabolic expenditure (based on the formula FAO/WHO/UN) multiplied by the coefficient of activity, which is calculated according to the physical activity of each participant. The calories provide to this group range between 1,400 and 1,800 kcal/day. The ration of macronutrients provided is 45-55 % arbohydrates,15-25 % proteins, and 25-35 % fat, in addition to a recommended intake of 20-40 g/day of fiber in the form of vegetables and fruits.
- DIETARY_SUPPLEMENT
-
Very Low Ketogenic Diet
The VLCKD ketogenic protocol entails: a caloric intake \< 800 calories, a protein intake calculated based on individual needs: 1.2 + 0.2 g/kg/ideal body weight, low carbohydrate content (approximately 45-55 g of carbohydrates per day), and low lipids (10-15g/day). Vitamins and minerals, Unlimited vegetables.
Sponsors & Collaborators
-
University of Palermo
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-11-30
- Primary Completion
- 2026-11-30
- Completion
- 2026-11-30
Countries
- Italy
Study Locations
More Related Trials
-
The Effects of Resveratrol Supplement on Biochemical Factors and Hepatic Fibrosis in Patients With Nonalcoholic Steatohepatitis
NCT02030977 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Evaluation of the Effectiveness of the Use of a Carnitine-Orotate Complex and Biphenyl Dimethyl Dicarboxylate in the Pathogenetic Therapy of Metabolic-associated Fatty Liver Disease: a Prospective Cohort Study
NCT06078722 ·Status: UNKNOWN
-
DEFINITION OF THE GENOMIC LANDSCAPE OF MASLD
NCT07249112 ·Status: RECRUITING ·Phase: NA
-
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease
NCT04330326 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of Dihydromiricetin on MASLD
NCT05052515 ·Status: COMPLETED ·Phase: NA
-
Effect of Indo-Mediterranean Diet on Hepatic Steatosis and Fibrosis in NAFLD Children
NCT05073588 ·Status: COMPLETED ·Phase: NA
-
Different Doses of ZED1227 vs. Placebo in NAFLD
NCT05305599 ·Status: COMPLETED ·Phase: PHASE2
-
Chrononutrition/ Chronotoxicity Intervention in People With Metabolic-associated Steatotic Liver Disease.
NCT06705868 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
GLP-1 RA on Liver OMICS in MASLD
NCT06982378 ·Status: NOT_YET_RECRUITING
-
Safety and Tolerability of Novel Medical Nutrition Products for NAFLD Treatment
NCT04308980 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Potential Benefits of Itopride in the Management of Patients With Metabolic Associated Fatty Liver Disease (MAFLD)
NCT05966025 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Probiotics in the Treatment of NAFLD
NCT02764047 ·Status: UNKNOWN ·Phase: NA
-
Nutritional Intervention IN Nash NON-ALCOHOLIC (NAFLD).
NCT05946330 ·Status: UNKNOWN ·Phase: NA
-
Mastiha Treatment for Obese With NAFLD Diagnosis
NCT03135873 ·Status: COMPLETED ·Phase: NA
-
Safety and Efficacy of Ketogenic Diet for Promoting Weight Loss in Obese Individuals With Compensated NASH Cirrhosis
NCT04383951 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Efficacy of a Natural Components Mixture in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)
NCT02369536 ·Status: COMPLETED ·Phase: NA
-
Screening for MASLD-related Advanced Fibrosis in Type 2 Diabetes
NCT07270822 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Influence of Diabetic Control on the Degree of Liver Fibrosis Assessed by Non-invasive Scores in Patients Followed in Diabetology
NCT05605821 ·Status: NOT_YET_RECRUITING
-
The Effect of Laparoscopic Splenectomy on Liver Reserve Function for Cirrhosis Patients
NCT05325424 ·Status: RECRUITING ·Phase: NA
-
Comparing Effects of Beetroot Juice and Mediterranean Diet on Liver Enzymes and Sonography in Patients With NAFLD
NCT05909631 ·Status: COMPLETED ·Phase: PHASE1
-
Effect of Lyophilized Cornus Mas L. on Anthropometric and Biochemical Parameters in Metabolic Associated Fatty Liver Disease Patients
NCT05546450 ·Status: COMPLETED ·Phase: NA
-
Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy
NCT01679197 ·Status: COMPLETED ·Phase: PHASE2
-
Resveratrol in Patients With Non-alcoholic Fatty Liver Disease
NCT01464801 ·Status: COMPLETED ·Phase: NA
-
Effect of Endoscopic Sleeve Gastroplasty in Patients With Obesity and MASH: A Randomized Controlled Trial
NCT06138821 ·Status: RECRUITING ·Phase: NA
-
Barriers to MASLD Management in Europe: Findings From a Multidisciplinary HCP-survey
NCT05765890 ·Status: COMPLETED